A Cambridge-based company has been awarded funding by Genomics England
for development of a platform for clinical genome analysis.
, a clinical genomics company, will further develop the SAPIENTIA platform created using technology originally developed by (and licensed from) the Wellcome Trust Sanger Institute, which led the UK arm of the international human genome project and remains the preminent UK genome sequencing and analysis centre. The SAPIENTA platform is said to offer a ‘scalable data analytics pipeline for the annotation and clinical interpretation of genomic sequence data’ suitable for research or clinical application.
Congenica’s CEO Dr Tom Weaver said the award was: “a measure of how critical the analysis tools we are developing will be for supporting national scale screening projects” including the 100,000 Genomes Project.